precisionmedicineonline4d
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
precisionmedicineonline5d
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
NEW YORK – Bristol Myers Squibb on Monday said the European Commission approved its PD-1 inhibitor Opdivo (nivolumab) plus the CTLA-4 inhibitor Yervoy (ipilimumab) as a first-line treatment for ...
precisionmedicineonline5d
European Commission Approves AstraZeneca's Tagrisso in Unresectable EGFR-Mutated NSCLC
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
precisionmedicineonline10d
Gene Therapy in 2024: 'Persistent' Approvals, Layoffs, and In Vivo Moving Toward the Clinic
NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...
precisionmedicineonline8d
Scipher Medicine, Atropos Health Partner to Add Immunology Data for AI Decision Support Tools
Scipher will contribute data derived from its PrismRA blood test to the Atropos Evidence Network, which underpins software tools, including an AI chatbot.
precisionmedicineonline8d
Institute for Follicular Lymphoma Innovation Invests $11M in PeproMene Bio's CAR T-Cell Therapy
NEW YORK – The Institute for Follicular Lymphoma Innovation (IFLI) is investing $11 million to advance PeproMene's BAFF-R targeting CAR T-cell therapy, PMB-CT01, as a treatment for patients with ...